Share This Article:

Development and Validation of Bioanalytical Method for Determination of Telmisartan and Hydrochlorothiazide Using HPTLC in Human Plasma

Abstract Full-Text HTML Download Download as PDF (Size:220KB) PP. 774-778
DOI: 10.4236/ajac.2012.311103    6,144 Downloads   8,818 Views   Citations

ABSTRACT

A simple, sensitive, rapid and economic high performance thin layer chromatographic method has been developed for determination of telmisartan and hydrochlorothiazide in human plasma using paracetamol as an internal standard. The plasma sample was extracted using mixture of methanol-acetonitrile (3.0:0.1, v/v). A concentration range from 200, 400, 600, 800, 1000, 1200 ng/spots were used for calibration curve of hydrochlorothiazide and telmisartan respectively. The percent recovery of telmisartan and hydrochlorothiazide was found to be75.98 and 81.91%. The mobile phase consists of chloroform: methanol: toluene (8:2:4 v/v/v). Densitometric analysis was carried out at wavelength 278 nm. The Rf values for hydrochlorothiazide, paracetamol and telmisartan were 0.28 ± 0.05, 0.50 ± 0.05, 0.66 ± 0.05 respectively. The stability of telmisartan and hydrochlorothiazide in plasma were confirmed during three freeze-thaw cycles (?20?C), on bench during 24 hours and post preparative during 48 hours. The proposed method was validated statistically and by performing recovery study for determination of telmisartan and hydrochlorothiazide in human plasma.

Cite this paper

A. Rote and P. Sonavane, "Development and Validation of Bioanalytical Method for Determination of Telmisartan and Hydrochlorothiazide Using HPTLC in Human Plasma," American Journal of Analytical Chemistry, Vol. 3 No. 11, 2012, pp. 774-778. doi: 10.4236/ajac.2012.311103.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] K. Wellington and D. M. Faulds, “Valsartan/Hydrochlorothiazide: A Review of Its Pharmacology, Therapeutic Efficacy and Place in the Management of Hypertension,” Drugs, Vol. 62, No. 13, 2002, pp. 1983-2005. doi:10.2165/00003495-200262130-00015
[2] H. Zhang, Y.-Y. Jiang, J. Wen, T. T. Zhou, G. R. Fan and Y. T. Wu, “Rapid Determination of Telmisartan in Human Plasma by HPLC Using a Monolithic Column with Fluorescence Detection and Its Application to a Bio-equivalence Study,” Journal of Chromatography B, Vol. 877, No. 29, 2009, pp. 3729-3733. doi:10.1016/j.jchromb.2009.08.028
[3] B.-M. Chen, Y.-Z. Liang, Y.-L. Wang, F.-L. Deng, P. Zhou, F.-Q. Guo and L.-F. Huang, “Development and Validation of Liquid Chromatography-Mass Spectrometry Method for the Determination of Telmisartan in Hu- man Plasma,” Analytica Chimica Acta, Vol. 540, No. 2, 2005, pp. 367-373. doi:10.1016/j.aca.2005.03.004
[4] H. Christel, L. Gl?sle-Schwarz, U. Kunz and U. Karst, “Determination of Telmisartan in Human Blood Plasma Part II: Liquid Chromatography-Tandem Mass Spectrometry Method Development, Comparison to Immunoassay and Pharmacokinetic Study,” Analytica Chimica Acta, Vol. 560, No. 1-2, 2006, pp. 41-49.
[5] M. del Rosario Brunetto, Y. Contreras, S. Clavijo, D. Torres, Y. Delgado, F. Ovalles, C. Ayala, M. Gallignani, J. M. Estela and V. C.Martin, “Determination of Losartan, Telmisartan, and Valsartan by Direct Injection of Human Urine into a Column-Switching Liquid Chromatographic System with Fluorescence Detection,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 50, No. 2, 2009, pp. 194-199
[6] A. R. Rote and S. P. Pingale, “Reverse Phase-HPLC and HPTLC Methods for Determination of Gemifloxacin Mesylate in Human Plasma,” Journal of Chromatography B, Vol. 877, No. 29, 2009, pp. 3719-3723. doi:10.1016/j.jchromb.2009.08.013
[7] D. Zendelovska, T. Stafilov and P. Milosevski, “Development of Solid-Phase Extraction Method and Its Application for Determination of Hydrochlorothiazide in Human Plasma Using HPLC,” Bio-medical Chromatography, Vol. 18, No. 2, 2004, pp. 71-76. doi:10.1002/bmc.293
[8] N. Erk, “Simultaneous Determination of Irbesartan and Hydrochlorothiazide in Human Plasma by Liquid Chromatography,” Journal of Chromatography B, Vol. 784, No. 1, 2003, pp. 195-201. doi:10.1016/S1570-0232(02)00759-6
[9] N. V. Ramakrishna, K. N. Vishwottam, S. Manoj, M. Koteshwara, S. Wishu and D. P. Varma, “Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Quantification of Hydrochlorothiazide in Human Plasma,” Biomedical Chromatography, Vol. 19, No. 10, 2005, pp. 751-760. doi:10.1002/bmc.510
[10] F. Liu, Y. Xu, S. Gao, J. Zhang and Q. Guo, “Determination of Hydrochlorothiazide in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 44, No. 5, 2007, pp. 1187-1191. doi:10.1016/j.jpba.2007.04.020
[11] S. Bansal and A. DeSte-fano, “Key Elements of Bioanalytical Method Validation for Small Molecules,” The AAPS Journal, Vol. 9, No. 1, 2007, pp. E109-E114. doi:10.1208/aapsj0901011
[12] US Department of Health and Human Services, “FDA Guidance for Industry: Bioanalytical Method Validation,” US Department of Health and Human Services, Rockville, 2001.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.